Nomic Bio

nomic.bio →

+34%

est. 2Y upside i

HealthcareSeries B

Nomic is doing for proteins what Illumina has done for DNA

Rank

#2328

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Low

Nomic Bio offers genuine long-term upside anchored by a differentiated nELISA platform and a disruptive $50 proteome price point, but the 2-year horizon is too compressed for a realistic liquidity event in a capital-intensive Canadian biotech that just completed its Series B in September 2024.

Last updated: May 14, 2026

Bull (20%)+180%

Omni 1000's $50-per-proteome price point becomes the dominant high-throughput standard, scaling revenue from $15.5M to $40M+ by 2028 and attracting a strategic acquisition by Thermo Fisher, Illumina, or a major pharma at a $400-500M exit valuation. That exit clears the ~$63M preference stack with substantial proceeds flowing to common equity, delivering strong per-share returns.

Base (50%)+35%

Broad Clinical Labs partnership and Omni 1000 grant programs drive modest adoption growth, lifting revenue to $22-25M by 2028 and supporting a Series C at approximately $220-250M post-money. High capital intensity and an additional dilutive financing round compress per-share gains; common equity captures roughly 65-70% of the nominal valuation lift after the $63M preference stack is accounted for.

Bear (30%)-65%

Thermo Fisher's incumbent pharma relationships and platform competition from Seer and Nautilus slow commercial adoption, holding revenue below $20M and forcing a flat or down Series C at $100-130M. With $63M in liquidation preferences, common equity holders receive minimal to no proceeds in a distressed sale or wind-down scenario.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

35%

Total funding of $63M against an estimated post-Series B valuation of ~$180-200M implies liquidation preferences consuming approximately 32-35% of company value before any proceeds reach common shareholders.

Dilution Risk

high

High capital intensity in contract proteomics and ongoing Omni 1000 platform scaling will almost certainly require a Series C financing, likely diluting current common equity by an estimated 15-25% before any liquidity event.

Secondary Liquidity

none

As a private Canadian biotech with 93 employees and no disclosed secondary market activity or tender offer history, employee equity has no practical near-term liquidity path outside a company-level exit event.

Questions to Ask at the Interview

Strategic questions based on Nomic Bio's data — designed to show you've done your homework.

1
“What was Nomic's revenue growth rate in 2025, and what is the internal target through the Omni 1000 commercial ramp — specifically, how many instruments or service contracts are in the pipeline versus the grant program?”
2
“What percentage of revenue is from recurring multi-year service contracts versus one-time project work, and how is the Broad Clinical Labs partnership structured — milestone-based, revenue-share, or volume commitments?”
3
“What was the Series B post-money valuation, what is the current 409A common stock strike price for new employee options, and what is the anticipated dilution from the next financing round?”

Community

Valuation Sentiment

Our model estimates +34% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.